10-K/A: Lantern Pharma Files Amendment to 10-K, Updates Executive and Director Information

Lantern Pharma files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Summary

• Lantern Pharma Inc. filed Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2024.
• The amendment updates Part III, Items 10 through 14, which were initially omitted in reliance on General Instruction G(3) to Form 10-K.
• The updated sections include information on directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, and principal accountant fees and services.
• The original Form 10-K was filed on March 27, 2025, and this amendment does not reflect events occurring after that date, except as expressly indicated.
• The amendment includes new certifications by the principal executive officer and principal financial officer.
• The aggregate market value of voting and non-voting common equity held by non-affiliates as of the last business day of the registrant's most recently completed second fiscal quarter was $44,285,965.
• As of April 28, 2025, the registrant had 10,784,725 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is primarily factual and corrective in nature. While the need for an amendment introduces a slightly negative element, the overall tone is neutral and focused on compliance.

Positives

• The company has taken steps to ensure compliance with SEC regulations by filing this amendment.
• The board consists of a majority of independent directors.
• The company has established an Audit Committee with a financial expert.
• The company has adopted a Code of Conduct and an Insider Trading Policy.
• Executive compensation includes both salary and bonus components, aligning with company performance.
• The company offers a 401(k) plan for its employees, including executive officers.

Negatives

• The need for an amendment suggests initial oversights in the original Form 10-K filing.
• The employment agreements for Panna Sharma and David Margrave formally expired on November 15, 2024, although certain terms continue to apply.
• Certain Bios Equity Entities hold substantial beneficial ownership interests in both the Company and Actuate, potentially creating conflicts of interest.

Risks

• The Cautionary Notice highlights the presence of forward-looking statements and the inherent risks and uncertainties in the company's business environment.
• The company operates in a competitive and rapidly changing environment, and new risks emerge from time to time.
• The company's success depends on its ability to predict and assess the impact of various factors on its business.
• Related party transactions, such as the purchase of shares from Bios Entities, could raise concerns about potential conflicts of interest.

Future Outlook

The document contains forward-looking statements, but does not provide a specific future outlook beyond what was included in the Original Form 10-K.

Management Comments

• The document includes certifications from Panna Sharma and David R. Margrave, attesting to the accuracy and completeness of the information presented in the amendment.

Industry Context

The company's focus on AI and genomics in developing precision therapeutics in oncology aligns with current trends in the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages appear to be in line with those offered by similar-sized biotechnology companies.
• The company's corporate governance practices, including the presence of independent directors and key committees, are consistent with Nasdaq listing requirements.
• The company's reliance on its RADR platform and collaborations with other companies like Actuate Therapeutics is a common strategy in the biotech industry to leverage expertise and resources.

Related Party Transactions

• On November 21, 2023, Lantern Pharma entered into separate Securities Purchase Agreements with Bios Fund I QP, LP and Bios Fund I, LP (the Bios Entities) pursuant to which Lantern Pharma agreed to purchase from the Bios Entities a total of 145,348 shares (the Shares) of Lantern Pharma's common stock, at a purchase price of $3.44 per share, for a total purchase price of $499,997.12.
• In May 2021, Lantern Pharma entered into a Collaboration Agreement with Actuate Therapeutics, Inc. (Actuate), a clinical stage private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis.

Stakeholder Impact

• The amendment provides stakeholders with more complete information about the company's leadership and governance.
• Executive compensation details offer transparency to shareholders.
• The disclosure of related party transactions allows stakeholders to assess potential conflicts of interest.

Next Steps

• The company will continue to file reports on Forms 10-K, 10-Q, and 8-K to disclose factors germane to its business.
• The company is evaluating the possibility of further collaborations with Actuate.

Key Dates

Keywords

Lantern Pharma, Form 10-K/A, Amendment, Executive Compensation, Directors, Corporate Governance, Financial Statements, Securities Exchange Act, Related Party Transactions, Audit Committee